Daily Medication Pearl: Anifrolumab-fnia (Saphnelo)

Anifrolumab-fnia is a human immunoglobulin G (IgG)1κ monoclonal antibody indicated for the treatment of moderate to severe systemic lupus erythematosus.

Medication Pearl of the Day: Anifrolumab-fnia (Saphnelo)

Indication: Saphnelo is a type I interferon (IFN) receptor antagonist indicated for the treatment of adult patients with moderate to severe systemic lupus erythematosus, who are receiving standard therapy.

Insight:

  • Dosing: The recommended dosage is 300 mg as an intravenous infusion over a 30-minute period every 4 weeks.
  • Dosage forms: Injection 300 mg/2 mL (150 mg/mL) in a single-dose vial.
  • Adverse events: Most common adverse drug reactions (incidence ≥5%) are nasopharyngitis, upper respiratory tract infections, bronchitis, infusion-related reactions, herpes zoster, and cough.
  • Mechanism of action: Anifrolumab-fnia is a human immunoglobulin G (IgG)1κ monoclonal antibody that binds to subunit 1 of the type I interferon receptor with high specificity and affinity. This binding inhibits type I IFN signaling, thereby blocking the biologic activity of type I IFNs.
  • Manufacturer: AstraZeneca

Sources:

Saphnelo full Prescribing Information (den8dhaj6zs0e.cloudfront.net)

saphnelo image - Google Search